To obtain consistent changes over time, the main analysis is actually of anomalies (departures from the climatological mean at each site) as these are more robust to
changes in data availability.
Not exact matches
Actual results and the timing of events could differ materially from those anticipated
in the forward - looking statements due to these risks and uncertainties as well as other factors, which include, without limitation: the uncertain timing of, and risks relating to, the executive search process; risks related to the potential failure of eptinezumab to demonstrate safety and efficacy
in clinical testing; Alder's ability to conduct clinical trials and studies of eptinezumab sufficient to achieve a positive completion; the
availability of
data at the expected times; the clinical, therapeutic and commercial value of eptinezumab; risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the manufacture of eptinezumab; Alder's ability to obtain and protect intellectual property rights, and operate without infringing on the intellectual property rights of others; the uncertain timing and level of expenses associated with Alder's development and commercialization activities; the sufficiency of Alder's capital and other resources; market competition;
changes in economic and business conditions; and other factors discussed under the caption «Risk Factors»
in Alder's Annual Report on Form 10 - K for the fiscal year ended December 31, 2017, which was filed with the Securities and Exchange Commission (SEC) on February 26, 2018, and is available on the SEC's website at www.sec.gov.
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth
in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures
in European countries that may increase the amount of discount required on Gilead's products; an increase
in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift
in payer mix to more highly discounted payer segments and geographic regions and decreases
in treatment duration;
availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations
in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations
in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials
in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations
in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates
in the timelines currently anticipated; Gilead's ability to receive regulatory approvals
in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy
data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta
in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to
changes in its stock price, corporate or other market conditions; fluctuations
in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time
in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
Examples of these risks, uncertainties and other factors include, but are not limited to the impact of: adverse general economic and related factors, such as fluctuating or increasing levels of unemployment, underemployment and the volatility of fuel prices, declines
in the securities and real estate markets, and perceptions of these conditions that decrease the level of disposable income of consumers or consumer confidence; adverse events impacting the security of travel, such as terrorist acts, armed conflict and threats thereof, acts of piracy, and other international events; the risks and increased costs associated with operating internationally; our expansion into and investments
in new markets; breaches
in data security or other disturbances to our information technology and other networks; the spread of epidemics and viral outbreaks; adverse incidents involving cruise ships;
changes in fuel prices and / or other cruise operating costs; any impairment of our tradenames or goodwill; our hedging strategies; our inability to obtain adequate insurance coverage; our substantial indebtedness, including the ability to raise additional capital to fund our operations, and to generate the necessary amount of cash to service our existing debt; restrictions
in the agreements governing our indebtedness that limit our flexibility
in operating our business; the significant portion of our assets pledged as collateral under our existing debt agreements and the ability of our creditors to accelerate the repayment of our indebtedness; volatility and disruptions
in the global credit and financial markets, which may adversely affect our ability to borrow and could increase our counterparty credit risks, including those under our credit facilities, derivatives, contingent obligations, insurance contracts and new ship progress payment guarantees; fluctuations
in foreign currency exchange rates; overcapacity
in key markets or globally; our inability to recruit or retain qualified personnel or the loss of key personnel; future
changes relating to how external distribution channels sell and market our cruises; our reliance on third parties to provide hotel management services to certain ships and certain other services; delays
in our shipbuilding program and ship repairs, maintenance and refurbishments; future increases
in the price of, or major
changes or reduction
in, commercial airline services; seasonal variations
in passenger fare rates and occupancy levels at different times of the year; our ability to keep pace with developments
in technology; amendments to our collective bargaining agreements for crew members and other employee relation issues; the continued
availability of attractive port destinations; pending or threatened litigation, investigations and enforcement actions;
changes involving the tax and environmental regulatory regimes
in which we operate; and other factors set forth under «Risk Factors»
in our most recently filed Annual Report on Form 10 - K and subsequent filings by the Company with the Securities and Exchange Commission.
The main findings
in this analysis are summarized
in Figure 7 and include the trend - line
changes from 1995 to 2011 for the
availability of sugars and sweeteners (FAOSTAT), the apparent consumption of refined sugars (ABS), and sugars added to carbonated soft drinks (industry
data) compared with the
changes in total sugars, added sugars, and sugars as soft drinks according to national dietary surveys
in 1995 and 2011 — 2012.
In the current study, we provide novel data on changes in the availability of added and refined sugars and in recorded intakes of total sugars, added sugars, SSB, carbonated soft drinks, juices, confectionery, and alcohol consumption in Australian adults and children between the 2 most recent national dietary surveys in 1995 and 2011 — 201
In the current study, we provide novel
data on
changes in the availability of added and refined sugars and in recorded intakes of total sugars, added sugars, SSB, carbonated soft drinks, juices, confectionery, and alcohol consumption in Australian adults and children between the 2 most recent national dietary surveys in 1995 and 2011 — 201
in the
availability of added and refined sugars and
in recorded intakes of total sugars, added sugars, SSB, carbonated soft drinks, juices, confectionery, and alcohol consumption in Australian adults and children between the 2 most recent national dietary surveys in 1995 and 2011 — 201
in recorded intakes of total sugars, added sugars, SSB, carbonated soft drinks, juices, confectionery, and alcohol consumption
in Australian adults and children between the 2 most recent national dietary surveys in 1995 and 2011 — 201
in Australian adults and children between the 2 most recent national dietary surveys
in 1995 and 2011 — 201
in 1995 and 2011 — 2012.
Objective: We investigated recent trends
in the
availability of sugars and sweeteners and
changes in intakes of total sugars, added sugars, and SSBs
in Australia by using multiple, independent
data sources.
«Though the annual burdens report won't reflect the effects of recent
changes for several years because of a lag
in the
availability of
data, New York's 2011 state - local tax burden — the highest
in the nation — shows just how necessary tax reform is
in New York,» Tax Foundation analyst Liz Malm said.
By cross-referencing these impacts with
data on local elephant populations, forest tree - species composition and structure, nutrient
availability, and understory growth
in existing Central African forests — both protected and unprotected ones alike — Poulsen and his team determined that up to 96 percent of all forests
in the region were susceptible to dramatic
changes if elephant populations shrank or disappeared.
«Our
data indicate that it is primarily food
availability, and not
changes in winter temperatures and hunting pressure, that determines where the geese stay
in winter,» says Kevin K. Clausen.
The paleoclimate
data, which included mainly
changes in the oxygen isotopes of the calcium carbonate deposits, were then compared to similar records from other caves, ice cores, and sediment records as well as model predictions for water
availability in the Middle East and west central Asia today and into the future.
It is important to the de-extinction effort because it shows (as our
data do) that passenger pigeon populations fluctuated
in size through time, as resource
availability changed.
The finding seems similar to «one small step for a man, one giant leap for mankind» — but instead, its «one small temperature
change but one giant argument for openness and transparency»
in data collection and selection methods, sites selected, algorithms and source code
availability and so on.
Many of the graphs
in this report illustrate historical
changes and future trends
in climate compared to some reference period, with the choice of this period determined by the purpose of the graph and the
availability of
data.
Limited
availability of
data and a variety of uncertainties relating to future
changes in climate, social and economic conditions, and the responses that will be made to address those
changes, frustrate precise cost and economic loss inventories.
Changes in instrumentation and
data availability have caused time - varying biases
in estimates of global - and regional - average sea - surface temperature.
New
data points to ways nutritionists might lobby for
changes in trade and food aid to improve the nutrient
availability for billions of people, researchers Jessica Fanzo and Stephen Wood say.2 months ago
CAS = Commission for Atmospheric Sciences CMDP = Climate Metrics and Diagnostic Panel CMIP = Coupled Model Intercomparison Project DAOS = Working Group on
Data Assimilation and Observing Systems GASS = Global Atmospheric System Studies panel GEWEX = Global Energy and Water Cycle Experiment GLASS = Global Land - Atmosphere System Studies panel GOV = Global Ocean
Data Assimilation Experiment (GODAE) Ocean View JWGFVR = Joint Working Group on Forecast Verification Research MJO - TF = Madden - Julian Oscillation Task Force PDEF = Working Group on Predictability, Dynamics and Ensemble Forecasting PPP = Polar Prediction Project QPF = Quantitative precipitation forecast S2S = Subseasonal to Seasonal Prediction Project SPARC = Stratospheric Processes and their Role
in Climate TC = Tropical cyclone WCRP = World Climate Research Programme WCRP Grand Science Challenges • Climate Extremes • Clouds, Circulation and Climate Sensitivity • Melting Ice and Global Consequences • Regional Sea - Ice
Change and Coastal Impacts • Water
Availability WCRP JSC = Joint Scientific Committee WGCM = Working Group on Coupled Modelling WGSIP = Working Group on Subseasonal to Interdecadal Prediction WWRP = World Weather Research Programme YOPP = Year of Polar Prediction
The ability to hindcast the detailed
changes in atmospheric composition over the past decade, particularly the variability of tropospheric O3 and CO, is limited by the
availability of measurements and their integration with models and emissions
data.
Thanks to the
availability of
data from satellite altimetry, Argo floats, and moored buoys
in the tropical Pacific, this decadal phase
change is the best - observed decadal climate shift
in history.
This shabby analysis has been debunked by Richard Telford http://quantpalaeo.wordpress.com/2014/12/26/not-phraud-but-phoolishness/ His conclusion: «The
changing geographic and seasonal patterns
in data availability means that simply calculating the mean pH for each year will give all sorts of spurious trends
in the analysis.
(a) Scientific, socio - economic, technical, and methodological issues, including the role of forests,
in particular tropical forests,
in the global carbon cycle; definitional issues, including those relating to links between deforestation and degradation;
data availability and quality; scale; rates and drivers of deforestation; estimation of
changes in carbon stocks and forest cover; and related uncertainties;
The introduction of Jio has fundamentally
changed the way Indians consume cellular
data, and wide
availability of 4G
data saw a dramatic boost
in sales of budget phones.
Toyota Engineering and Manufacturing North America (Princeton,
IN) 10/2001 — 5/2010 Technician / Skilled Maintenance Team Leader • Provided support and technical expertise on Allen Bradley PLC - 5 and Control Logic, as well as designed new screens for HMI using RSView and mapped all
data and alarms needed for monitoring production equipment • Programmed PLC's using Rockwell software as required by production, utilizing PLC as a troubleshooting tool to locate and repair process problems • Repaired and maintained all three phase medium and low voltage motors, programming medium voltage control relays to meet manufacturer specifications and monitor applicable
data from motors as well as engineering
data and motor manufacturing parameters into VFD's • Established PM schedules for maintaining floor conveyors, robots, RFID, air handling, sludge, paint mix room, and lifters, assisting T / M's with performing preventative maintenance on equipment • Ensured calibration of environmental equipment to maintain state and federal guidelines, performing the calibration procedures and repair of micrometers, calipers, and profilometers as required by ISO standards • Identified and developed countermeasures to manufacturing - related problems with equipment, monitoring corrective actions and resolution implementation to ensure problems were below 2 % of operational
availability • Review associated work instructions for
changes as needed to maintain quality, safety, and environmental standards, while planning and coordinating weekly safety meetings and training for team members
In reporting against each of the headline indicators and strategic change indicators in the first report, the Steering Committee has noted limitations in data availability and qualit
In reporting against each of the headline indicators and strategic
change indicators
in the first report, the Steering Committee has noted limitations in data availability and qualit
in the first report, the Steering Committee has noted limitations
in data availability and qualit
in data availability and quality.
The
availability of this second wave of
data allows researchers to look at
change over a 5 - year period
in relationships or to examine the effect of relationship characteristics at W1 on some later outcome.
This report from 2009 examines the
availability of housing
data on a country - by - country basis and assembles roughly comparable
data over a significant time period to identify
changing price levels
in the international housing markets.